Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Geert R. A. M. D'Haens"'
Autor:
Koos P. J. van Dam, Adriaan G. Volkers, Luuk Wieske, Eileen W. Stalman, Laura Y. L. Kummer, Zoé L. E. van Kempen, Joep Killestein, Sander W. Tas, Laura Boekel, Gerrit J. Wolbink, Anneke J. van der Kooi, Joost Raaphorst, R. Bart Takkenberg, Geert R. A. M. D’Haens, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederike J. Bemelman, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Cécile A. C. M. van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Renée C. F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, Papay B. P. Jallah, Esther Brusse, Pieter A. van Doorn, Adája E. Baars, Dirk Jan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Maurice Steenhuis, Sofie Keijzer, Jim B. D. Keijser, Olvi Cristianawati, Anja ten Brinke, Niels J. M. Verstegen, S. Marieke van Ham, Theo Rispens, Taco W. Kuijpers, Mark Löwenberg, Filip Eftimov, on behalf of the T2B! Immunity against SARS-CoV-2 study group
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-
Externí odkaz:
https://doaj.org/article/8a6e2bdaa5404154a54ecf8fcb54843c
Autor:
Luuk Wieske, Laura Y. L. Kummer, Koos P. J. van Dam, Eileen W. Stalman, Anneke J. van der Kooi, Joost Raaphorst, Mark Löwenberg, R. Bart Takkenberg, Adriaan G. Volkers, Geert R. A. M. D’Haens, Sander W. Tas, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederike J. Bemelman, Joep Killestein, Zoé L. E. van Kempen, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Gertjan Wolbink, Laura Boekel, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Cornelia F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, B. Papay Jallah, Esther Brusse, Pieter A. van Doorn, Adája E. Baars, Dirkjan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Maurice Steenhuis, Theo Rispens, Anja ten Brinke, Niels J. M. Verstegen, Koos A. H. Zwinderman, S. Marieke van Ham, Taco W. Kuijpers, Filip Eftimov, on behalf of the T2B! immunity against SARS-CoV-2 study group
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-6 (2022)
Abstract Background Studies have suggested incremental short-term adverse events (AE) after repeated vaccination. In this report, we assessed occurrence and risk factors for short-term AEs following repeated SARS-CoV-2 vaccination in patients with va
Externí odkaz:
https://doaj.org/article/67db8621c3964b7a9443d09b66e09e5f
Publikováno v:
Drugs in R&D, Vol 19, Iss 2, Pp 227-234 (2019)
Abstract Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with considerable disease burden. We review some current misconceptions about UC in adults with the aim of optimizing care for patients. Although UC and Crohn’s dis
Externí odkaz:
https://doaj.org/article/b50ea5061cae491390a3aad47cbf4402
Autor:
Laura Boekel, Eileen W Stalman, Luuk Wieske, Femke Hooijberg, Koos P J van Dam, Yaëlle R Besten, Laura Y L Kummer, Maurice Steenhuis, Zoé L E van Kempen, Joep Killestein, Adriaan G Volkers, Sander W Tas, Anneke J van der Kooi, Joost Raaphorst, Mark Löwenberg, R Bart Takkenberg, Geert R A M D'Haens, Phyllis I Spuls, Marcel W Bekkenk, Annelie H Musters, Nicoline F Post, Angela L Bosma, Marc L Hilhorst, Yosta Vegting, Frederike J Bemelman, Alexandre E Voskuyl, Bo Broens, Agner Parra Sanchez, Cécile A C M van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J G M Verschuuren, Annabel M Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Cornelia F Allaart, Y K Onno Teng, Pieter van Paassen, Matthias H Busch, Papay B P Jallah, Esther Brusse, Pieter A van Doorn, Adája E Baars, Dirk Jan Hijnen, Corine R G Schreurs, W Ludo van der Pol, H Stephan Goedee, Erik H Vogelzang, Maureen Leeuw, Sadaf Atiqi, Ronald van Vollenhoven, Martijn Gerritsen, Irene E van der Horst-Bruinsma, Willem F Lems, Mike T Nurmohamed, Maarten Boers, Sofie Keijzer, Jim Keijser, Carolien van de Sandt, Arend Boogaard, Olvi Cristianawati, Anja ten Brinke, Niels J M Verstegen, Koos A H Zwinderman, S Marieke van Ham, Theo Rispens, Taco W Kuijpers, Gertjan Wolbink, Filip Eftimov, Rivka de Jongh, Lisan Kuijper, Mariel Duurland, Ruth Hagen, Jet van den Dijssel, Christine Kreher, Amelie Bos, Viriginia Palomares Cabeza, Veronique Konijn, George Elias, Juan Vallejo, Marrit van Gils, Tom Ashhurst, Sergey Nejentsev, Elham Mirfazeli
Publikováno v:
The Lancet Rheumatology, 4(6), e417-e429. Lancet Publishing Group
The Lancet. Rheumatology, 4, e417-e429
T2B! immunity against SARS-CoV-2 study group 2022, ' Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants : a substudy of two prospective cohort studies ', The Lancet Rheumatology, vol. 4, no. 6, pp. e417-e429 . https://doi.org/10.1016/S2665-9913(22)00102-3
The Lancet Rheumatology, 4(6), E417-E429. ELSEVIER
The Lancet. Rheumatology, 4, 6, pp. e417-e429
The Lancet. Rheumatology, 4(6), e417-e429. Elsevier Ltd
The Lancet Rheumatology, 4(6), e417-e429. Elsevier
The Lancet. Rheumatology, 4, e417-e429
T2B! immunity against SARS-CoV-2 study group 2022, ' Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants : a substudy of two prospective cohort studies ', The Lancet Rheumatology, vol. 4, no. 6, pp. e417-e429 . https://doi.org/10.1016/S2665-9913(22)00102-3
The Lancet Rheumatology, 4(6), E417-E429. ELSEVIER
The Lancet. Rheumatology, 4, 6, pp. e417-e429
The Lancet. Rheumatology, 4(6), e417-e429. Elsevier Ltd
The Lancet Rheumatology, 4(6), e417-e429. Elsevier
Contains fulltext : 251784.pdf (Publisher’s version ) (Closed access) BACKGROUND: Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough infections in vaccinated patients with immune-mediated inflammatory diseases treated with imm
Autor:
Sonja I. Gringhuis, Tanja M. Kaptein, Ester B. M. Remmerswaal, Agata Drewniak, Brigitte A. Wevers, Bart Theelen, Geert R. A. M. D’Haens, Teun Boekhout, Teunis B. H. Geijtenbeek
Publikováno v:
Nature Immunology, 23(12), 1735-1748. Nature Publishing Group
Nature immunology, 23(12), 1735-1748. Nature Publishing Group
Nature immunology, 23(12), 1735-1748. Nature Publishing Group
The non-pathogenic TH17 subset of helper T cells clears fungal infections, whereas pathogenic TH17 cells cause inflammation and tissue damage; however, the mechanisms controlling these distinct responses remain unclear. Here we found that fungi sensi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb95b9e0a1be7f25f872ff5b9849bad7
https://pure.knaw.nl/portal/en/publications/02768b71-10f2-4c54-9daa-117c4aec0199
https://pure.knaw.nl/portal/en/publications/02768b71-10f2-4c54-9daa-117c4aec0199
Autor:
Luuk Wieske, Koos P J van Dam, Maurice Steenhuis, Eileen W Stalman, Laura Y L Kummer, Zoé L E van Kempen, Joep Killestein, Adriaan G Volkers, Sander W Tas, Laura Boekel, Gerrit J Wolbink, Anneke J van der Kooi, Joost Raaphorst, Mark Löwenberg, R Bart Takkenberg, Geert R A M D'Haens, Phyllis I Spuls, Marcel W Bekkenk, Annelie H Musters, Nicoline F Post, Angela L Bosma, Marc L Hilhorst, Yosta Vegting, Frederike J Bemelman, Alexandre E Voskuyl, Bo Broens, Agner Parra Sanchez, Cécile A C M van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J G M Verschuuren, Annabel M Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Renée C F Allaart, Y K Onno Teng, Pieter van Paassen, Matthias H Busch, Papay B P Jallah, Esther Brusse, Pieter A van Doorn, Adája E Baars, Dirk Jan Hijnen, Corine R G Schreurs, W Ludo van der Pol, H Stephan Goedee, Sofie Keijzer, Jim B D Keijser, Arend Boogaard, Olvi Cristianawati, Anja ten Brinke, Niels J M Verstegen, Koos A H Zwinderman, S Marieke van Ham, Taco W Kuijpers, Theo Rispens, Filip Eftimov, R. de Jongh, C.E. van de Sandt, L. Kuijper, M. Duurland, R.R. Hagen, J. van den Dijssel, C. Kreher, A. Bos, V. Palomares Cabeza, V.A.L. Konijn, G. Elias, J.G. Vallejo, M.J. van Gils, T.M. Ashhurst, S. Nejentsev, E.S. Mirfazeli
Publikováno v:
The Lancet Rheumatology, 4(5), e338-e350. Elsevier
The Lancet. Rheumatology, 4(5), e338-e350. Elsevier Ltd
The Lancet Rheumatology, 4(5), E338-E350. ELSEVIER
T2B! immunity against SARS-CoV-2 study group 2022, ' Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants : a cohort study ', The Lancet Rheumatology, vol. 4, no. 5, pp. e338-e350 . https://doi.org/10.1016/S2665-9913(22)00034-0
The Lancet Rheumatology, 4(5), e338-e350. Lancet Publishing Group
The Lancet Rheumatology, 4(5), E338-E350. Lancet Publishing Group
The Lancet. Rheumatology, 4(5), e338-e350. Elsevier Ltd
The Lancet Rheumatology, 4(5), E338-E350. ELSEVIER
T2B! immunity against SARS-CoV-2 study group 2022, ' Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants : a cohort study ', The Lancet Rheumatology, vol. 4, no. 5, pp. e338-e350 . https://doi.org/10.1016/S2665-9913(22)00034-0
The Lancet Rheumatology, 4(5), e338-e350. Lancet Publishing Group
The Lancet Rheumatology, 4(5), E338-E350. Lancet Publishing Group
Background: Disease-specific studies have reported impaired humoral responses after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders treated with specific immunosuppressants. Disease-overarching studies, and data on reca
Autor:
Maria L Haasnoot, Aart Mookhoek, Marjolijn Duijvestein, Geert R A M D’Haens, Albert J Bredenoord
Publikováno v:
Haasnoot, Maria L; Mookhoek, Aart; Duijvestein, Marjolijn; D'Haens, Geert R A M; Bredenoord, Albert J (2023). Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis. Inflammatory bowel diseases, 29(1), pp. 62-69. Lippincott Williams & Wilkins 10.1093/ibd/izac044
Inflammatory Bowel Diseases, 29, 1, pp. 62-69
Inflammatory Bowel Diseases, 29, 62-69
Inflammatory Bowel Diseases, 29, 1, pp. 62-69
Inflammatory Bowel Diseases, 29, 62-69
Background It has been suggested that eosinophils may be a prognostic marker of disease outcome in ulcerative colitis (UC), but conflicting data exist. The objective was to investigate the extent of mucosal eosinophils and peripheral blood eosinophil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee474570c23f5307a10dbffa7db39982
Autor:
Corine A. Lansdorp, Christianne J. Buskens, Krisztina B. Gecse, Mark Löwenberg, Jaap Stoker, Willem A. Bemelman, Geert R. A. M. D’Haens, Rob A. Hulst
Publikováno v:
United European Gastroenterol J
United European Gastroenterology Journal, 10(2), 160-168. SAGE Publications Inc.
Lansdorp, C A, Buskens, C J, Gecse, K B, Löwenberg, M, Stoker, J, Bemelman, W A, D’Haens, G R A M & van Hulst, R A 2022, ' Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease : Results of the HOT-TOPIC trial after 1-year follow-up ', United European Gastroenterology Journal, vol. 10, no. 2, pp. 160-168 . https://doi.org/10.1002/ueg2.12189
United European gastroenterology journal, 10(2), 160-168. SAGE Publications Inc.
United European Gastroenterology Journal, 10(2), 160-168. SAGE Publications Inc.
Lansdorp, C A, Buskens, C J, Gecse, K B, Löwenberg, M, Stoker, J, Bemelman, W A, D’Haens, G R A M & van Hulst, R A 2022, ' Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease : Results of the HOT-TOPIC trial after 1-year follow-up ', United European Gastroenterology Journal, vol. 10, no. 2, pp. 160-168 . https://doi.org/10.1002/ueg2.12189
United European gastroenterology journal, 10(2), 160-168. SAGE Publications Inc.
Background: Previously published short-term results (week 16) of this trial showed a significant improvement in clinical, radiologic and biochemical outcomes in Crohn's disease patients with therapy-refractory perianal fistulas after treatment with h
Autor:
Sonja I, Gringhuis, Tanja M, Kaptein, Ester B M, Remmerswaal, Agata, Drewniak, Brigitte A, Wevers, Bart, Theelen, Geert R A M, D'Haens, Teun, Boekhout, Teunis B H, Geijtenbeek
Publikováno v:
Nature immunology.
The non-pathogenic T
P097 FAVORABLE SAFETY PROFILE FOR AMISELIMOD, A SELECTIVE S1P RECEPTOR MODULATOR, IN CROHN’S DISEASE
Publikováno v:
Inflammatory Bowel Diseases. 26:S1-S2
Background Sphingosine 1-phosphate (S1P) receptor modulators are being developed to treat autoimmune-mediated diseases, including ulcerative colitis (UC) and Crohn’s disease (CD). Amiselimod (AMS), a second-generation S1P receptor modulator, was de